AstraZeneca: Lynparza Demonstrated Clinically Meaningful Prolonged Survival Benefit in Early Breast Cancer in OlympiA Phase III Trial
December 12, 2024
December 12, 2024
WILMINGTON, Delaware, Dec. 12 (TNSres) -- AstraZeneca, a biopharmaceutical company, issued the following news release:
* * *
87.5% of patients treated with LYNPARZA were alive at six years vs. 83.2% in the
comparator arm
First and only PARP inhibitor to improve survival in early breast cancer
* * *
Updated results from the OlympiA Phase III trial showed AstraZeneca and Merck & Co., Inc's, known as MSD outside . . .
* * *
87.5% of patients treated with LYNPARZA were alive at six years vs. 83.2% in the
comparator arm
First and only PARP inhibitor to improve survival in early breast cancer
* * *
Updated results from the OlympiA Phase III trial showed AstraZeneca and Merck & Co., Inc's, known as MSD outside . . .